Soligenix Company Description

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States.

The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet’s Disease.

The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19.

The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009.

Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Soligenix, Inc.

Country	United States
Founded	1987
Industry	Pharmaceutical Preparations
Employees	15
CEO	Christopher Schaber

Contact Details

Address: 29 Emmons Drive Princeton, Delaware 08540 United States
Phone	609 538 8200
Website	soligenix.com

Stock Details

Ticker Symbol	0A6I
Exchange	London Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2834

Key Executives

Name	Position
Christopher Schaber	Chief Executive Officer
Jonathan Guarino	Chief Financial Officer